Is the fu­ture of di­a­betes drugs in dual GIP and GLP-1 in­cretin re­cep­tor ag­o­nists? That's the $47M ques­tion for Car­mot

Near­ly three years af­ter clos­ing its Se­ries B, Car­mot Ther­a­peu­tics has re­turned to the fundrais­ing well with a new round. And this time they brought …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.